HER3 in cancer: from the bench to the bedside

Gandullo-Sánchez, Lucía; Ocaña, Alberto; Pandiella, Atanasio

doi:10.1186/s13046-022-02515-x

Cited by 21 publications

(3 citation statements)

References 283 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ERBB3 is rarely mutated in LUAD based on the cosmic database ( https://cancer.sanger.ac.uk ). ERBB3 encodes a member of the epidermal growth factor receptor family of receptor tyrosine kinases and plays an important role in several cancers ( Gandullo-Sanchez et al , 2022 ).…”

Section: Resultsmentioning

confidence: 99%

WMDS.net: a network control framework for identifying key players in transcriptome programs

et al. 2023

View full text Add to dashboard Cite

Motivation Mammalian cells can be transcriptionally reprogrammed to other cellular phenotypes. Controllability of such complex transitions in transcriptional networks underlying cellular phenotypes is an inherent biological characteristic. This network controllability can be interpreted by operating a few key regulators to guide the transcriptional program from one state to another. Finding the key regulators in the transcriptional program can provide key insights into the network state transition underlying cellular phenotypes. Results To address this challenge, here we proposed to identify the key regulators in the transcriptional co-expression network as a minimum dominating set (MDS) of driver nodes that can fully control the network state transition. Based on the theory of structural controllability, we developed a weighted MDS network model (WMDS.net) to find the drive nodes of differential gene co-expression networks. The weight of WMDS.net integrates the degree of nodes in the network and the significance of gene co-expression difference between two physiological states into the measurement of node controllability of the transcriptional network. To confirm its validity, we applied WMDS.net to the discovery of cancer driver genes in RNA-seq datasets from The Cancer Genome Atlas. WMDS.net is powerful among various cancer datasets and outperformed the other top-tier tools with a better balance between precision and recall. Availability https://github.com/chaofen123/WMDS.net. Supplementary information Supplementary data are available at Bioinformatics online.

show abstract

Section: Resultsmentioning

confidence: 99%

WMDS.net: a network control framework for identifying key players in transcriptome programs

et al. 2023

View full text Add to dashboard Cite

show abstract

“…RTKs control important functions in tissue homeostasis, cell function, and mammalian development. These functions include tissue repair and regeneration, organ morphogenesis, cell proliferation and survival, and neovascularization 7–11 . Therefore, gaining a deeper understanding of RTKs can help identify potential targets for cancer detection and therapy.…”

Section: Introductionmentioning

confidence: 99%

“…These functions include tissue repair and regeneration, organ morphogenesis, cell proliferation and survival, and neovascularization. [7][8][9][10][11] Therefore, gaining a deeper understanding of RTKs can help identify potential targets for cancer detection and therapy. This review focuses on the classification and structure of RTKs, the mechanisms of normal and oncogenic activation, their expression in high-incidence tumors, and the different types of targeted drugs.…”

Section: Introductionmentioning

confidence: 99%

Receptor tyrosine kinases: biological functions and anticancer targeted therapy

Zhang,

2023

MedComm

View full text Add to dashboard Cite

Receptor tyrosine kinases (RTKs) are a class of protein kinases that play crucial roles in various cellular processes, including cell migration, morphological differentiation, cell growth, and angiogenesis. In humans, 58 RTKs have been identified and categorized into 20 distinct families based on the composition of their extracellular regions. RTKs are primarily activated by specific ligands that bind to their extracellular region. They not only regulate tumor transformation, proliferation, metastasis, drug resistance, and angiogenesis, but also initiate and maintain the self‐renewal and cloning ability of cancer stem cells. Accurate diagnosis and grading of tumors with dysregulated RTKs are essential in clinical practice. There is a growing body of evidence supporting the benefits of RTKs‐targeted therapies for cancer patients, and researchers are actively exploring new targets and developing targeted agents. However, further optimization of RTK inhibitors is necessary to effectively target the diverse RTK alterations observed in human cancers. This review provides insights into the classification, structure, activation mechanisms, and expression of RTKs in tumors. It also highlights the research advances in RTKs targeted anticancer therapy and emphasizes their significance in optimizing cancer diagnosis and treatment strategies.

show abstract

New era for emerging therapeutic targeting human epidermal growth factor receptor 3 (HER 3) in advanced nonsmall cell lung cancer and metastatic breast cancer

et al. 2022

View full text Add to dashboard Cite

Human epidermal growth factor receptor 3 (HER3) is a member of the transmembrane receptor tyrosine kinase family. Upregulation of HER3 pathway has been implicated as a mechanism of resistance in solid tumors, particularly in estrogen receptor positive, HER2 positive breast cancer and epidermal growth factor (EGFR) mutant nonsmall cell lung cancer. Several studies suggest that HER3 overexpression represents a negative prognostic biomarker associated with poor survival. Preclinical and clinical studies of anti‐HER3 investigational therapies suggest that expression of the HER3 ligand, neuregulin, may predict response to treatment. Despite its emergence as a key cancer therapeutic target, HER3 cannot be targeted with traditional tyrosine kinase inhibitors therapy due to its weak kinase activity. Monoclonal and bispecific antibodies targeting HER3 have been developed and tested in early phase trials. Objective responses were limited when first‐generation HER3‐specific monoclonal antibodies were investigated as monotherapies in phase 1 and 2 clinical trials for nonsmall cell lung cancer (NSCLC) and metastatic breast cancer (MBC). MBC and NSCLC HER3 specific antibody‐drug conjugates have shown encouraging results in resistance in cancer cells, particularly in those that overexpress HER3. These agents have shown some promise in early phase trials in both NSCLC and MBC setting in heavily pretreated patients with varying degrees of response. It is unclear which subgroup of patients will truly benefit from targeting HER3 as these therapies are under investigation.

show abstract

HER3 in cancer: from the bench to the bedside

Cited by 21 publications

References 283 publications

WMDS.net: a network control framework for identifying key players in transcriptome programs

WMDS.net: a network control framework for identifying key players in transcriptome programs

Receptor tyrosine kinases: biological functions and anticancer targeted therapy

New era for emerging therapeutic targeting human epidermal growth factor receptor 3 (HER 3) in advanced nonsmall cell lung cancer and metastatic breast cancer

Contact Info

Product

Resources

About